Lalit Kalra1, John Hodsoll2, Saddif Irshad2, David Smithard2, Dulka Manawadu2. 1. From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.). lalit.kalra@kcl.ac.uk. 2. From the Department of Basic and Clinical Neurosciences (L.K., S.I.), Institute of Psychiatry, Psychology and Neurosciences, and Biostatistics Department (J.H.), NIHR Biomedical Research Centre for Mental Health and Institute of Psychiatry, Psychology and Neurosciences, King's College London, UK; University of Kent (D.S.), Canterbury, UK; and King's College Hospital NHS Foundation Trust, London, UK (D.M.).
Abstract
OBJECTIVE: To investigate whether nasogastric tubes (NGTs) increase poststroke pneumonia (PSP), mortality, or poor outcomes in nil-by-mouth acute stroke patients. METHODS: This study analyzed prespecified outcomes of PSP at 14 days and mortality and function measured by the modified Rankin Scale at 90 days in 1,217 nil-by-mouth stroke patients at ≤48 hours of symptom onset in a multicenter randomized controlled trial of preventive antibiotics between April 21, 2008, and May 17, 2014. Generalized mixed models adjusted for age, comorbidities, stroke type and severity, and quality of care were used. No patients were lost to follow-up at 14 days, and 36 (3%) were lost at 90 days. RESULTS: Patients with NGT (298 of 1,217 [24.4%]) had more severe strokes (median NIH Stroke Scale score 17 vs 14, p = 0.0001) and impaired consciousness (39% vs 28%, p = 0.001). NGT did not increase PSP (43 of 298 [14.4%] vs 80 of 790 [10.1%], adjusted odds ratio [OR] 1.26 [95% confidence interval (CI) 0.78-2.03], p = 0.35) or 14- and 90-day mortality (33 of 298 [11.1%] vs 78 of 790 [9.9%], adjusted OR 1.10 [95% CI 0.67-1.78], p = 0.71; and 79 of 298 [26.5%] vs 152 of 790 [19.2%], adjusted OR 0.95 [95% CI 0.67-1.33], p = 0.75, respectively). Ninety-day modified Rankin Scale score distribution was comparable between groups (adjusted OR 1.14 [95% CI 0.87-1.56], p = 0.08). PSP independently increased 90-day mortality (40 of 123 [32.5%] vs 191 of 965 [19.8%], adjusted OR 1.71 [95% CI 1.11-2.65], p = 0.015) and was not prevented by antibiotics in patients with NGT (adjusted OR 1.1 [95% CI 0.89-1.54], p = 0.16). CONCLUSIONS: Early NGT does not increase PSP incidence, mortality, or poor functional outcomes and can be used safely in acute stroke patients.
OBJECTIVE: To investigate whether nasogastric tubes (NGTs) increase poststroke pneumonia (PSP), mortality, or poor outcomes in nil-by-mouth acute stroke patients. METHODS: This study analyzed prespecified outcomes of PSP at 14 days and mortality and function measured by the modified Rankin Scale at 90 days in 1,217 nil-by-mouth stroke patients at ≤48 hours of symptom onset in a multicenter randomized controlled trial of preventive antibiotics between April 21, 2008, and May 17, 2014. Generalized mixed models adjusted for age, comorbidities, stroke type and severity, and quality of care were used. No patients were lost to follow-up at 14 days, and 36 (3%) were lost at 90 days. RESULTS: Patients with NGT (298 of 1,217 [24.4%]) had more severe strokes (median NIH Stroke Scale score 17 vs 14, p = 0.0001) and impaired consciousness (39% vs 28%, p = 0.001). NGT did not increase PSP (43 of 298 [14.4%] vs 80 of 790 [10.1%], adjusted odds ratio [OR] 1.26 [95% confidence interval (CI) 0.78-2.03], p = 0.35) or 14- and 90-day mortality (33 of 298 [11.1%] vs 78 of 790 [9.9%], adjusted OR 1.10 [95% CI 0.67-1.78], p = 0.71; and 79 of 298 [26.5%] vs 152 of 790 [19.2%], adjusted OR 0.95 [95% CI 0.67-1.33], p = 0.75, respectively). Ninety-day modified Rankin Scale score distribution was comparable between groups (adjusted OR 1.14 [95% CI 0.87-1.56], p = 0.08). PSP independently increased 90-day mortality (40 of 123 [32.5%] vs 191 of 965 [19.8%], adjusted OR 1.71 [95% CI 1.11-2.65], p = 0.015) and was not prevented by antibiotics in patients with NGT (adjusted OR 1.1 [95% CI 0.89-1.54], p = 0.16). CONCLUSIONS: Early NGT does not increase PSP incidence, mortality, or poor functional outcomes and can be used safely in acute stroke patients.
Authors: Amit K Kishore; Andy Vail; Angel Chamorro; Javier Garau; Stephen J Hopkins; Mario Di Napoli; Lalit Kalra; Peter Langhorne; Joan Montaner; Christine Roffe; Anthony G Rudd; Pippa J Tyrrell; Diederik van de Beek; Mark Woodhead; Andreas Meisel; Craig J Smith Journal: Stroke Date: 2015-04-09 Impact factor: 7.914
Authors: Hans-Christian Koennecke; W Belz; D Berfelde; M Endres; S Fitzek; F Hamilton; P Kreitsch; B-M Mackert; D G Nabavi; C H Nolte; W Pöhls; I Schmehl; B Schmitz; M von Brevern; G Walter; P U Heuschmann Journal: Neurology Date: 2011-08-24 Impact factor: 9.910
Authors: Willeke F Westendorp; Jan-Dirk Vermeij; Elles Zock; Imke J Hooijenga; Nyika D Kruyt; Hans J L W Bosboom; Vincent I H Kwa; Martijn Weisfelt; Michel J M Remmers; Robert ten Houten; A H C M Tobien Schreuder; Sarah E Vermeer; Ewout J van Dijk; Diederik W J Dippel; Marcel G W Dijkgraaf; Lodewijk Spanjaard; Marinus Vermeulen; Tom van der Poll; Jan M Prins; Frederique H Vermeij; Yvo B W E M Roos; Ruud P Kleyweg; Henk Kerkhoff; Matthijs C Brouwer; Aeilko H Zwinderman; Diederik van de Beek; Paul J Nederkoorn Journal: Lancet Date: 2015-01-20 Impact factor: 79.321
Authors: Willeke F Westendorp; Paul J Nederkoorn; Jan-Dirk Vermeij; Marcel G Dijkgraaf; Diederik van de Beek Journal: BMC Neurol Date: 2011-09-20 Impact factor: 2.474